The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Anthem Biosciences Ltd

Anthem Biosciences Ltd

BSE 544449 · NSE ANTHEM · ISIN INE0CZ201020 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Biotechnology

₹900.60

-2.54%

BSE close, 28 August 2026

Market cap

₹50,740.53 cr

56.3 cr shares · Mid cap

Free float

₹9,689.97 cr

as published

P/E · P/B

81.3× · —

EPS ₹11.08 · BV —

FY25-26 rev / PAT

2,089.31 / 670.56

₹ cr, as filed

Filings, window

14

7 selected · 50%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹579.45 52-WK HIGH ₹942.00 ₹900.60 89% of range
Against 52-week high-4.4%
Against 52-week low+55.4%
Day change-2.54%
Size bandMid cap
Index membershipNIFTY 500

Valuation as published by BSE

Earnings per share₹11.08
Price / earnings81.28×
Price / book—
Book value — derived, price ÷ P/B—
Return on equity—
Operating margin41.54%
Net margin26.58%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 383.84 102.01 1.81 41.54% 26.58%
Mar-26 · Q 582.50 211.66 3.77 56.41% 36.34%
FY25-26 2,089.31 670.56 11.95 48.30% 32.09%

Quarter on quarter

Revenue, quarter on quarter
-34.1%
Net profit, quarter on quarter
-51.8%
Operating margin, quarter on quarter
-1,487 bps

Disclosure profile 14 filings in the window

0 median 17.0 p75 · 25 sector max 52 14 39th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Investor Presentation2
Press Release2
Board Outcome1
Concall Transcript1
Results1
Selected sub-total7
Procedural
AGM / EGM2
Analyst / Investor Meet1
Compliance Certificate1
General1
Newspaper Publication1
Trading Window1
Procedural sub-total7
Total14

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

14 filings · 7 selected · busiest 2026-07-21

Filing rhythm · the twelve most recent

2026-07-212026-10-09

SelectedProcedural

Filings

14 in the window · 14 earlier on record

  1. 9 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Reg 74(5) of DP Regulations

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 24 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation of closure of Trading Window for Q2FY27

    Insider Trading / SAST / Closure of Trading Window View filing →

  3. 8 September 2026 ·

    General

    Settlement Of Upside Sharing Arrangement

    Intimation of the settlement of Upside Sharing Arrangement

    Company Update / General View filing →

  4. 27 July 2026 ·

    Concall Transcript

    Earnings Call Transcript

    Transcript of Earnings Conference Call held on July 22, 2026.

    Company Update / Earnings Call Transcript View filing →

  5. 24 July 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Anthem Biosciences Limited has submitted the Exchange the voting results and a copy of scrutinizer report of the 20th Annual General Meeting of the Company held on July 22, 2026

    AGM/EGM / AGM View filing →

  6. 22 July 2026 ·

    AGM / EGM

    Announcement Under

    Anthem Biosciences Limited has informed the Exchange regarding the Proceedings of the 20th Annual General Meeting held on Wednesday, July 22, 2026

    AGM/EGM / AGM View filing →

  7. 22 July 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audio recording of Earnings Call for the quarter ended June 30, 2026.

    Company Update / Analyst / Investor Meet View filing →

  8. 22 July 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Publication on Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026

    Company Update / Newspaper Publication View filing →

  9. 21 July 2026 ·

    Press Release

    Press Release / Media Release (Revised)

    Revised Press Release on Unaudited Financial Results for the quarter ended June 30, 2026

    Company Update / Press Release / Media Release (Revised) View filing →

  10. 21 July 2026 ·

    Investor Presentation

    Investor Presentation

    Revised Investor Presentation for Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026

    Company Update / Investor Presentation View filing →

  11. 21 July 2026 ·

    Press Release

    Press Release / Media Release

    Press Release on Consolidated Financial Results for the quarter ended June 30, 2026

    Company Update / Press Release / Media Release View filing →

  12. 21 July 2026 ·

    Investor Presentation

    Investor Presentation

    Investor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026`

    Company Update / Investor Presentation View filing →

  13. 21 July 2026 ·

    Results

    Financial Results For The Quarter Ended June 30, 2026

    Financials Results for the quarter ended June 30, 2026

    Result / Financial Results View filing →

  14. 21 July 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of The Board Meeting Held On Tuesday, July 21, 2026

    Outcome of the Board Meeting held on Tuesday, July 21, 2026

    Board Meeting / Outcome of Board Meeting View filing →

RSS feed for Anthem Biosciences Ltd · the 50 most recent filings